Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese.
Ashlan J Kunz CoyneCarolina OrzolMichael P VeveMichael Joseph RybakPublished in: Open forum infectious diseases (2023)
HABP/VABP, those who were morbidly obese had significantly greater odds of presumed treatment failure when compared with those who were non-morbidly obese.
Keyphrases
- obese patients
- bariatric surgery
- weight loss
- pseudomonas aeruginosa
- adipose tissue
- metabolic syndrome
- type diabetes
- ejection fraction
- end stage renal disease
- escherichia coli
- newly diagnosed
- healthcare
- gram negative
- prognostic factors
- emergency department
- patient reported outcomes
- staphylococcus aureus
- patient reported
- acute respiratory distress syndrome
- combination therapy
- respiratory failure
- mechanical ventilation